Hong Kong (Company Announcement) – This announcement is made by Genscript Biotech Corpo­ra­tion (the “Company”, together with its sub­sid­i­aries, the “Group”) with respect to a second report recently issued by Flaming Research (“Flaming”) (the “Second Report”) which con­tains alle­ga­tions against the Company, and is published by the Company pursuant to Rule 13.09 of the Rules Governing the Listing of Securities (the “Listing Rules”) on The Stock Exchange of Hong Kong Limited (the “Stock Exchange”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) (the “SFO”).

Reference is made to the announcement of the Company dated 28 September 2018 in rela­tion­ to the Report and the Company’s refutation and/or clarification of the alle­ga­tions made in the Report (the “Announcement”). Unless other­wise defined, capitalized terms used in this announcement shall have the same meanings as defined in the Announcement.

The Company denies all of the alle­ga­tions against the Group in the Second Report. The Second Report com­prises state­ments which are mis­lead­ing, biased, selective, inaccurate and incomplete as well as ground­less alle­ga­tions and irresponsible spec­u­la­tions. The man­agement of the Company reiterated that it has no record of being contacted by Flaming before and after the Report or the Second Report was pub­lished.

The Company hereby solemnly reminded Flaming and the relevant persons who orchestrated the publication of the Report and the Second Report to seriously con­sider that the Company has taken nec­es­sary legal actions with respect to the Report and the Second Report. If the publication of mis­lead­ing, biased, selective, inaccurate and incomplete as well as ground­less alle­ga­tions and irresponsible spec­u­la­tions con­tinues with the attempt to damage the Company’s corporate image, credit and repu­ta­tion, cause sig­nif­i­cant fluctuation in the share price of the Company, and disrupt the securities trading market, the Company will take all nec­es­sary legal actions until Flaming and the relevant persons in rela­tion­ to the matters set out in the Report and the Second Report are subject to fair and reason­able judgment by the law and the market.

The man­agement and scientists of the Company hereby invite qualified research institutes with disclosed identity to engage in open and public discussion, but firmly oppose the conduct of Flaming with undisclosed identity under the disguise of a research institute to damage the Company’s repu­ta­tion. The Company is committed to under­take all nec­es­sary legal actions to protect the legal interests of the Company.

Shareholders and poten­tial in­­vestors of the Company are advised to exercise caution when dealing in the securities of the Company.

Source: Genscript.